🇺🇸 Human insulin isophane suspension in United States

22 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pleural Effusion — 3 reports (13.64%)
  2. Pneumonia — 3 reports (13.64%)
  3. Anaphylactoid Reaction — 2 reports (9.09%)
  4. Asthenia — 2 reports (9.09%)
  5. Blood Creatine Phosphokinase Mb Increased — 2 reports (9.09%)
  6. Blood Glucose Increased — 2 reports (9.09%)
  7. Blood Pressure Increased — 2 reports (9.09%)
  8. Chest Discomfort — 2 reports (9.09%)
  9. Feeling Cold — 2 reports (9.09%)
  10. Paraesthesia — 2 reports (9.09%)

Source database →

Human insulin isophane suspension in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Human insulin isophane suspension approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Human insulin isophane suspension in United States?

Eli Lilly and Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.